| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8285623 | Parkinsonism & Related Disorders | 2018 | 7 Pages |
Abstract
Although promising, TOMs are underutilized in clinical trials of neurodegenerative disorders. Validating relevant endpoints, standardizing measures and procedures, establishing a single platform for integration of data and algorithms from different devices, and facilitating regulatory approvals should advance TOMs integration into clinical trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Carlo Alberto Artusi, Murli Mishra, Patricia Latimer, Joaquin A. Vizcarra, Leonardo Lopiano, Walter Maetzler, Aristide Merola, Alberto J. Espay,